Besides, the use of bortezomib in MTC may be straightened by the results obtained with drugs not evaluated in patients with MTC, namely MDM2-inhibitors and HDAC-inhibitors. This evidence concerns the gene HDAC9 and medullary thyroid gland carcinoma.